Cite

HARVARD Citation

    Smith, J. et al. (2023). Tumor immune microenvironment alterations using induction cetuximab in a phase II trial of deintensified therapy for p16‐positive oropharynx cancer. Head & neck. 45 (5), pp. 1281-1287. [Online]. 
  
Back to record